decisionhealth Newsletters, Answer Books - 2007 Issue 8 (August)
Appendix E - National Coverage Determinations Manual / Blood Brain Barrier Osmotic Disruption for Treatment of Brain Tumors 110.20
Subscribe or sign in to view the full article.
Article Overview
This page covers a Medicare National Coverage Determination from the National Coverage Determinations Manual dealing with blood brain barrier osmotic disruption in the context of brain tumor treatment. It is relevant to hospital and oncology coding and reimbursement teams, compliance staff, and clinicians working with Medicare coverage policy. The article provides the policy background, the covered and non-covered indication sections, the effective and implementation dates, and a brief statement about what the policy does not change.
Why This Topic Matters
Medicare coverage policy can affect whether a service is payable and how associated services are reported. Understanding the scope of this determination helps users distinguish the procedure policy from chemotherapy coverage and align billing and compliance workflows with current federal guidance.
Article Sections
-
A. General
Provides background on the blood brain barrier and describes the general clinical context for osmotic disruption in brain tumor treatment. It also notes the types of services involved in the overall process.
-
B. Nationally Covered Indications
States the coverage status for nationally covered indications under this determination.
-
C. Nationally Non-Covered Indications
Identifies the Medicare coverage determination effective date and the general non-covered status for the service when used in the specified treatment context.
-
D. Other
Clarifies the relationship of this policy to anti-cancer chemotherapy coverage and notes the last review date.
What You Will Learn
- The Medicare policy framework for this blood brain barrier procedure
- How the article organizes general background, coverage, and non-coverage sections
- The dates associated with the determination and its review cycle
- How the policy relates to broader anti-cancer chemotherapy coverage
Who Should Read This
- Medical coders
- Hospital billing staff
- Compliance professionals
- Oncology practice administrators
- Clinicians involved in Medicare-covered services
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com